Coronavirus disease -19 (COVID-19). The confirmed diagnosis of COVID-19
Conditions
Interventions
Intervention group: Plasma exchange (1.5 to 2 liter) with colloidal solution containing 4-5% albumin and fresh frozen plasma (FFP) for two consecutive days, and plasma therapy with convalescent plasma
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Positive Real Time-Polymerase Chain Reaction test of COVID-19
Exclusion criteria
Exclusion criteria: History of renal disease and dialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size of lesion on lung. Timepoint: On day 1, day 4,day 7, day 14, and day 28 after the treatment. Method of measurement: CT scan, Millimeter.;Body temperature. Timepoint: On day 1, day 4,day 7, day 14, and day 28 after the treatment. Method of measurement: Thermometer, Celsius.;The ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage). Timepoint: On day 1, day 4,day 7, day 14, and day 28 after the treatment. Method of measurement: Ventilator, Millimeter of mercury (mmHg).;Respiratory rate. Timepoint: On day 1, day 4,day 7, day 14, and day 28 after the treatment. Method of measurement: Pulse oximeter, Breaths per minute.;Serum level of Interleukin 1. Timepoint: Before and after the treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA), Milligrams per deciliter.;Serum level of Interleukin 6. Timepoint: Before and after the treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA), Milligrams per deciliter.;Serum level of Interleukin 10. Timepoint: Before and after the treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA), Milligrams per deciliter.;Serum level of tumor necrosis factor alpha. Timepoint: Before and after the treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA), Milligrams per deciliter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anti- corona virus immune globulin G level. Timepoint: Before and after the treatment. Method of measurement: Enzyme-linked immunosorbent assay (ELISA), Milligrams per deciliter.;Mortality rate. Timepoint: During the study. Method of measurement: Mortality formula.;Oxygen saturation. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Pulse oximetry.;Lymphocyte count. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Cell counter, Cell per milliliter.;CD3+ cell count. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Flowcytometer, Cell per milliliter.;CD4+ cell count. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Flowcytometer, Cell per milliliter.;CD8+ cell count. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Flowcytometer, Cell per milliliter.;Alanine aminotransferase level. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Autoanalyzer, Unit per liter.;Aspartate aminotransferase level. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Autoanalyzer, Unit per liter.;Total bilirubin level. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Autoanalyzer, Milligram per deciliter.;Direct bilirubin level. Timepoint: On day 1, day 4, day 7, day 14, and day 28 after the treatment. Method of measurement: Autoanalyzer, Milligram per deciliter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Hajifathali
Shahid Beheshti University of Medical Sciences
Outcome results
None listed